Acute Kidney Injury: Diagnostic Approach and Management

Acute kidney injury (AKI) is a sudden decline in kidney function characterized by an increase in serum creatinine and/or decrease in urine output. According to the Kidney Disease Improving Global Outcomes (KDIGO) criteria, AKI is defined by any of the following within 48 hours:

• Increase in serum creatinine ≥26.5 μmol/L (0.3 mg/dL)
• Increase in serum creatinine to ≥1.5 times baseline within 7 days
• Urine volume <0.5 mL/kg/h for 6 hours

AKI Classification System:

AKI is traditionally classified into three categories based on the anatomical location of the primary insult:

1. Pre-renal AKI (60-70%): Results from decreased renal perfusion with structurally normal kidneys
2. Intrinsic (Intrarenal) AKI (25-30%): Direct damage to kidney parenchyma
3. Post-renal AKI (5-10%): Obstruction of urinary flow

Early recognition and appropriate classification are crucial for timely intervention and improved outcomes. The diagnostic approach involves careful history-taking, physical examination, laboratory studies, and imaging to determine the underlying cause and guide management strategies.

Pre-renal AKI results from decreased effective renal perfusion while maintaining normal kidney structure. The kidneys respond appropriately to hypoperfusion by conserving sodium and water, leading to concentrated urine with low sodium content.

Common Causes:

Hypovolemia:

• Hemorrhage, dehydration
• GI losses (vomiting, diarrhea)
• Renal losses (diuretics, diabetes insipidus)
• Third-spacing (burns, pancreatitis)

Decreased Effective Circulating Volume:

• Heart failure
• Liver cirrhosis with ascites
• Nephrotic syndrome
• Sepsis with vasodilation

Renal Vasoconstriction:

• NSAIDs, ACE inhibitors, ARBs
• Hepatorenal syndrome
• Contrast-induced nephropathy

Diagnostic Features:

Pathophysiology: Reduced renal perfusion activates the renin-angiotensin-aldosterone system (RAAS) and stimulates antidiuretic hormone (ADH) release. This leads to efferent arteriole constriction, increased sodium and water reabsorption, and concentrated urine production. If perfusion is not restored, prolonged ischemia can progress to acute tubular necrosis.

Management: Treatment focuses on restoring renal perfusion through volume resuscitation, optimizing cardiac output, and discontinuing nephrotoxic medications. Prompt intervention can often reverse pre-renal AKI completely.

Intrinsic AKI involves direct damage to kidney parenchyma, most commonly affecting the tubules (acute tubular necrosis), but can also involve glomeruli, interstitium, or vessels.

Classification by Anatomical Location:

Tubular (85% of intrinsic AKI):

• Acute Tubular Necrosis (ATN):
  • Ischemic: Prolonged hypoperfusion, surgery, shock
  • Nephrotoxic: Aminoglycosides, contrast agents, chemotherapy, rhabdomyolysis

Glomerular:

• Rapidly progressive glomerulonephritis (RPGN)
• Post-infectious glomerulonephritis
• Systemic lupus erythematosus
• Anti-GBM disease (Goodpasture syndrome)

Interstitial:

• Acute interstitial nephritis (AIN)
• Drug-induced (NSAIDs, antibiotics, PPIs)
• Infection-related
• Systemic diseases (sarcoidosis, SLE)

Vascular:

• Acute cortical necrosis
• Malignant hypertension
• Thrombotic microangiopathy
• Renal artery/vein thrombosis

Diagnostic Features:

• FENa >2% (>1% if on diuretics)
• Urine osmolality <350 mOsm/kg
• Urine sodium >40 mEq/L
• BUN:Creatinine ratio <15:1

Urinalysis Findings:

• ATN: Muddy brown casts, epithelial cells
• Glomerular: RBC casts, proteinuria, hematuria
• Interstitial: WBC casts, eosinophiluria
• Vascular: Normal or minimal findings

Management: Treatment is primarily supportive with focus on identifying and treating underlying causes, avoiding further nephrotoxic exposure, and providing renal replacement therapy when indicated.

Post-renal AKI results from obstruction of urine flow anywhere from the renal pelvis to the urethral meatus. Bilateral obstruction or unilateral obstruction in a solitary kidney is required to cause significant AKI.

Common Causes by Location:

Upper Urinary Tract:

• Nephrolithiasis (bilateral or solitary kidney)
• Ureteral strictures
• Retroperitoneal fibrosis
• Malignancy (cervical, prostate, bladder)
• Blood clots

Lower Urinary Tract:

• Benign prostatic hyperplasia (BPH)
• Prostate cancer
• Bladder cancer
• Urethral strictures
• Neurogenic bladder
• Medications (anticholinergics)

Pathophysiology: Obstruction leads to increased intratubular pressure, decreased GFR, and eventual tubular damage if prolonged. Initially, the kidney attempts to maintain filtration through compensatory mechanisms, but sustained obstruction results in irreversible nephron loss.

Clinical Presentation:

• Oliguria or anuria (may be intermittent)
• Flank pain or suprapubic pain
• Nausea and vomiting
• Signs of uremia if prolonged

Diagnostic Approach:

Suspected Post-renal AKI | Bladder scan/ Foley catheter | ┌─────────┴─────────┐ │ Large residual │ Normal residual │ volume │ volume │ │ ▼ ▼ Lower tract Renal ultrasound obstruction | ┌────┴────┐ │ Hydro- │ Normal │ nephrosis│ │ │ ▼ ▼ Upper tract Consider obstruction other causes

Management: Prompt decompression is essential to preserve renal function. Methods include urethral catheterization, nephrostomy tubes, or ureteral stents depending on obstruction level.

Accurate diagnosis of AKI requires systematic evaluation combining clinical assessment, laboratory studies, and imaging. The diagnostic approach should efficiently differentiate between pre-renal, intrinsic, and post-renal causes.

Primary Diagnostic Algorithm:

Acute Kidney Injury Suspected (↑ Creatinine, ↓ Urine output) | History & Physical Basic labs + Urinalysis | ┌────┴────┐ │ Volume │ Normal volume │ depletion│ status │ │ ▼ ▼ Fluid trial Bladder scan │ + Renal US │ | ▼ ┌────┴────┐ Response? │ Obstruction│ No obstruction │ │ present │ ├─Yes→Pre-renal ▼ │ Intrinsic AKI └─No→Consider workup ATN

Fractional Excretion of Sodium (FENa):

FENa = (UNa × PCr) / (PNa × UCr) × 100

Where: U = urine, P = plasma, Na = sodium, Cr = creatinine

Interpretation:

• FENa <1%: Pre-renal AKI
• FENa >2%: Intrinsic AKI
• FENa 1-2%: Indeterminate

Fractional Excretion of Urea (FEUrea): More reliable when diuretics are used:

FEUrea = (UUrea × PCr) / (PUrea × UCr) × 100

• FEUrea <35%: Pre-renal
• FEUrea >50%: Intrinsic

Comprehensive Laboratory Workup:

Urinalysis Interpretation:

• Hyaline casts: Normal finding
• Muddy brown casts: Acute tubular necrosis
• RBC casts: Glomerular disease
• WBC casts: Interstitial nephritis, pyelonephritis
• Eosinophils: Drug-induced interstitial nephritis

AKI management requires a multifaceted approach addressing the underlying cause while providing supportive care to prevent complications and optimize recovery.

General Management Principles:

1. Identify and Treat Underlying Cause

• Restore renal perfusion in pre-renal AKI
• Remove nephrotoxins and treat specific conditions in intrinsic AKI
• Relieve obstruction in post-renal AKI

2. Medication Management

Medication Review Checklist: ├─ Discontinue nephrotoxins │ ├─ NSAIDs │ ├─ Aminoglycosides │ ├─ Vancomycin │ └─ Contrast agents ├─ Adjust dosing for GFR │ ├─ Renally cleared drugs │ └─ Monitor levels └─ Avoid further exposure ├─ ACE/ARB (temporarily) └─ Diuretics (unless volume overload)

3. Fluid and Electrolyte Management

• Monitor daily weights and fluid balance
• Restrict fluid if oliguric
• Correct electrolyte abnormalities:
  • Hyperkalemia: >5.5 mEq/L requires intervention
  • Metabolic acidosis: Bicarbonate if pH <7.2
  • Hyperphosphatemia: Phosphate binders
  • Hypocalcemia: Calcium replacement if symptomatic

4. Nutritional Support

• Protein restriction: 0.8-1.0 g/kg/day if conservative management
• Increase to 1.2-1.5 g/kg/day if on dialysis
• Limit potassium and phosphorus intake
• Ensure adequate caloric intake

5. Prevention of Complications

• Infection prevention: Avoid unnecessary catheters
• GI protection: PPI if high bleeding risk
• DVT prophylaxis: Appropriate anticoagulation
• Monitor for uremic complications

Renal Replacement Therapy Indications:

Absolute Indications (AEIOU mnemonic):

• Acidosis: Severe metabolic acidosis (pH <7.1)
• Electrolyte abnormalities: Hyperkalemia >6.5 mEq/L
• Intoxications: Methanol, ethylene glycol, salicylates
• Overload: Pulmonary edema refractory to diuretics
• Uremia: Pericarditis, encephalopathy, bleeding

Relative Indications:

• Progressive azotemia despite optimal management
• Oliguria >72 hours
• BUN >100 mg/dL (35.7 mmol/L)

Recovery and Prognosis: Recovery depends on cause, duration, and patient factors. Most pre-renal AKI resolves completely with appropriate treatment. Intrinsic AKI recovery varies widely, with ATN typically showing gradual improvement over weeks to months.

Certain clinical scenarios require specific diagnostic and management approaches in AKI. Recognition of these situations is crucial for optimal patient care.

Contrast-Induced AKI (CI-AKI):

• Definition: >25% increase in creatinine within 48-72 hours of contrast exposure
• Risk factors: Pre-existing CKD, diabetes, volume depletion, high contrast volume
• Prevention strategies:
  • Pre-hydration with normal saline
  • Use lowest contrast volume possible
  • Consider N-acetylcysteine (controversial efficacy)
  • Avoid nephrotoxic medications

Drug-Induced AKI:

Rhabdomyolysis-Associated AKI:

• Pathophysiology: Myoglobin precipitation, tubular obstruction, direct nephrotoxicity
• Diagnosis: CK >5000 U/L, myoglobinuria, hyperkalemia, hyperphosphatemia
• Management:
  • Aggressive fluid resuscitation (target urine output 1-3 mL/kg/h)
  • Urine alkalinization (controversial)
  • Monitor and treat electrolyte abnormalities
  • Early RRT if severe

Cardiorenal Syndrome: Bidirectional interaction between heart and kidney dysfunction:

Cardiorenal Syndrome Classification: ├─ Type 1: Acute heart failure → AKI ├─ Type 2: Chronic heart failure → CKD ├─ Type 3: AKI → Acute cardiac dysfunction ├─ Type 4: CKD → Chronic cardiac disease └─ Type 5: Systemic disease → Combined dysfunction

Hepatorenal Syndrome (HRS):

• Occurs in patients with advanced liver disease
• Functional kidney failure with normal histology
• HRS-1: Rapid progression (<2 weeks)
• HRS-2: Slower progression (months)
• Treatment: Vasoconstrictors (terlipressin, midodrine + octreotide) + albumin

Tumor Lysis Syndrome:

• Massive cell death releases intracellular contents
• Hyperkalemia, hyperphosphatemia, hyperuricemia, hypocalcemia
• Prevention: Allopurinol, rasburicase, aggressive hydration
• Monitor electrolytes every 6 hours during high-risk chemotherapy

Elderly Considerations:

• Baseline creatinine may underestimate GFR due to decreased muscle mass
• Higher risk for drug accumulation
• More susceptible to volume depletion and overload
• Careful medication reconciliation essential

Pregnancy-Related AKI:

• Pre-eclampsia/HELLP syndrome
• Acute fatty liver of pregnancy
• Postpartum hemolytic uremic syndrome
• Requires multidisciplinary management with obstetrics